Targeting stromal cell sialylation reverses T cell-mediated immunosuppression in the tumor microenvironment
- PMID: 37167967
- DOI: 10.1016/j.celrep.2023.112475
Targeting stromal cell sialylation reverses T cell-mediated immunosuppression in the tumor microenvironment
Abstract
Immunosuppressive tumor microenvironments (TMEs) reduce the effectiveness of immune responses in cancer. Mesenchymal stromal cells (MSCs), precursors to cancer-associated fibroblasts (CAFs), promote tumor progression by enhancing immune cell suppression in colorectal cancer (CRC). Hyper-sialylation of glycans promotes immune evasion in cancer through binding of sialic acids to their receptors, Siglecs, expressed on immune cells, which results in inhibition of effector functions. The role of sialylation in shaping MSC/CAF immunosuppression in the TME is not well characterized. In this study, we show that tumor-conditioned stromal cells have increased sialyltransferase expression, α2,3/6-linked sialic acid, and Siglec ligands. Tumor-conditioned stromal cells and CAFs induce exhausted immunomodulatory CD8+ PD1+ and CD8+ Siglec-7+/Siglec-9+ T cell phenotypes. In vivo, targeting stromal cell sialylation reverses stromal cell-mediated immunosuppression, as shown by infiltration of CD25 and granzyme B-expressing CD8+ T cells in the tumor and draining lymph node. Targeting stromal cell sialylation may overcome immunosuppression in the CRC TME.
Keywords: CP: Cancer; CP: Immunology; T cell exhaustion; T cells; cancer-associated fibroblasts; colon cancer; immunotherapy; inflammation; sialylation; siglecs; stromal cells; tumor microenvironment.
Copyright © 2023 The Author(s). Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests L.P., W.G., J.C., and P.J. are employees and shareholders of Palleon Pharmaceuticals. M.E.O'D. is a founder of ONK Therapeutics and a member of its Board of Directors and is co-inventor on two related patents (US20210186999A1 and US2017032727899A1). K.L., T.R., and A.E.R. are co-inventors on patent US20210186999A1.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous
